問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


E-DA Hospital (在職)

Digestive System Department

E-DA Hospital (在職)

Digestive System Department

更新時間：2023-09-19

陳子皓
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳子皓

List

18Cases

2024-09-01 - 2028-07-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-09-01 - 2025-01-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2022-02-01 - 2024-05-10

Phase I

Completed
A Phase 1b, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Treatment With JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, HBeAg-negative Participants With Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Hepatitis B, Chronic

  • Test Drug

    JNJ-73763989 JNJ-64300535

Participate Sites
2Sites

Recruiting2Sites

2022-06-30 - 2024-05-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-09-01 - 2027-12-31

Phase II

Active
A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    ATL

Participate Sites
14Sites

Not yet recruiting5Sites

Recruiting9Sites

2023-01-05 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-01 - 2028-06-30

Phase II

Active
A Phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United)

  • Condition/Disease

    chronic hepatitis B

  • Test Drug

    Daplusiran/Tomligisiran (GSK5637608) Bepirovirsen (GSK3228836)

Participate Sites
4Sites

Recruiting4Sites

2023-02-15 - 2025-06-30

Phase I

Completed
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    注射劑 注射劑

Participate Sites
10Sites

Terminated10Sites

2024-09-01 - 2027-07-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2022-06-30 - 2023-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB